Dyne Net Income Per Share from 2010 to 2026

DYN Stock  USD 17.70  0.34  1.88%   
Dyne Therapeutics Net Loss yearly trend continues to be very stable with very little volatility. Net Loss is likely to drop to -4.07. During the period from 2010 to 2026, Dyne Therapeutics Net Loss quarterly data regression pattern had range of 14.3536 and standard deviation of  3.78. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
(3.88)
Current Value
(4.07)
Quarterly Volatility
3.7807112
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Dyne Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dyne Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.9 M, Interest Expense of 2.5 M or Selling General Administrative of 74.6 M, as well as many indicators such as Price To Sales Ratio of 6.54, Dividend Yield of 0.0 or PTB Ratio of 3.36. Dyne financial statements analysis is a perfect complement when working with Dyne Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Dyne Stock
Check out the analysis of Dyne Therapeutics Correlation against competitors.
To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.
Evaluating Dyne Therapeutics's Net Income Per Share across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Dyne Therapeutics's fundamental strength.

Latest Dyne Therapeutics' Net Income Per Share Growth Pattern

Below is the plot of the Net Income Per Share of Dyne Therapeutics over the last few years. It is Dyne Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Dyne Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Income Per Share10 Years Trend
Very volatile
   Net Income Per Share   
       Timeline  

Dyne Net Income Per Share Regression Statistics

Arithmetic Mean(2.86)
Coefficient Of Variation(132.13)
Mean Deviation2.63
Median(2.93)
Standard Deviation3.78
Sample Variance14.29
Range14.3536
R-Value0
Mean Square Error15.25
R-Squared0.0000016
Significance1.00
Slope0.0009
Total Sum of Squares228.70

Dyne Net Income Per Share History

2026 -4.07
2025 -3.88
2024 -3.37
2023 -3.95
2022 -3.23
2021 -2.93
2020 -1.24

About Dyne Therapeutics Financial Statements

Dyne Therapeutics investors utilize fundamental indicators, such as Net Income Per Share, to predict how Dyne Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss(3.88)(4.07)

Pair Trading with Dyne Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dyne Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dyne Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Dyne Stock

  0.58LION Lionsgate Studios HoldingPairCorr
  0.57ARDX Ardelyx Sell-off TrendPairCorr
  0.55JRVR James River GroupPairCorr
  0.46PGEN PrecigenPairCorr
  0.46CUB Lionheart HoldingsPairCorr
The ability to find closely correlated positions to Dyne Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Dyne Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Dyne Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Dyne Therapeutics to buy it.
The correlation of Dyne Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Dyne Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Dyne Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Dyne Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Dyne Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dyne Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dyne Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dyne Therapeutics Stock:
Check out the analysis of Dyne Therapeutics Correlation against competitors.
To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Will Biotechnology sector continue expanding? Could Dyne diversify its offerings? Factors like these will boost the valuation of Dyne Therapeutics. Projected growth potential of Dyne fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Dyne Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(3.62)
Return On Assets
(0.34)
Return On Equity
(0.61)
The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Dyne Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dyne Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Dyne Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.